Q BioMed Inc. (QBIO)
QBIO Stock Price Chart
Explore Q BioMed Inc. interactive price chart. Choose custom timeframes to analyze QBIO price movements and trends.
QBIO Company Profile
Discover essential business fundamentals and corporate details for Q BioMed Inc. (QBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jun 2015
Employees
3.00
Website
https://www.qbiomed.comCEO
Denis D. Corin
Description
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
QBIO Financial Timeline
Browse a chronological timeline of Q BioMed Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 21 Feb 2025
Earnings released on 15 Nov 2024
Earnings released on 28 Aug 2024
Earnings released on 31 May 2024
Earnings released on 12 Feb 2024
Earnings released on 22 Nov 2023
Earnings released on 16 Jun 2023
EPS came in at -$0.02 .
Earnings released on 26 May 2023
EPS came in at $0.08 surpassing the estimated $0.04 by +100.00%, while revenue for the quarter reached $2.50K , missing expectations by -99.99%.
Earnings released on 9 Apr 2023
EPS came in at $0.03 , while revenue for the quarter reached $12.54K .
Earnings released on 3 Nov 2022
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $26.27K , missing expectations by -99.67%.
Earnings released on 28 Jul 2022
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%, while revenue for the quarter reached $170.49K , beating expectations by +62.37%.
Earnings released on 14 Apr 2022
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $75.06K , missing expectations by -97.50%.
Earnings released on 28 Feb 2022
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $104.92K , missing expectations by -89.51%.
Earnings released on 15 Oct 2021
EPS came in at -$0.07 surpassing the estimated -$0.12 by +41.67%, while revenue for the quarter reached $45.68K , missing expectations by -90.87%.
Earnings released on 15 Jul 2021
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $45.00K , missing expectations by -10.00%.
Earnings released on 14 Apr 2021
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%, while revenue for the quarter reached $40.59K .
Earnings released on 1 Mar 2021
EPS came in at -$0.15 falling short of the estimated -$0.08 by -87.50%.
Earnings released on 14 Oct 2020
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $15.00K , beating expectations by +22.22%.
QBIO Stock Performance
Access detailed QBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.